11 March 2025 : Clinical Research
New-Onset, But Not Chronic Atrial Fibrillation, Is a Significant Factor Contributing to Mortality Among Patients with Severe COVID-19
Jakub Klimkiewicz
1ABDEF*, Mateusz Gutowski 1ABDE, Andrzej Michałowski1ABDE, Kamil Paryż 1ABDE, Anna Klimkiewicz2ACDEF, Arkadiusz Lubas 3ACDEF
DOI: 10.12659/MSM.946192
Med Sci Monit 2025; 31:e946192
Table 2 Comparison of new-onset atrial fibrillation (NOAF) group and control group.
| NOAF n=31Mean±SDMedian [IQR]or n (%) | Control n=253Mean±SDMedian [IQR]or n (%) | p-value | |
|---|---|---|---|
| Age (years) | 69.3 SD 8.669 []9 | 63.6 ±15.767 []22 | 0.073 |
| Female gender | 1445.2% | 10240.3% | 0.604 |
| Male gender | 1754.8% | 15159.7% | 0.604 |
| Obesity | 1032.2% | 4718.6% | 0.07 |
| Diabetes | 1238.7% | 5622.1% | 0.041 |
| Hypertension | 18(58%) | 140(55.3%) | 0.772 |
| Ischemic heart disease | 39.7% | 3212.6% | 0.634 |
| Heart failure | 39.7% | 166.3% | 0.480 |
| History of myocardial infarction | 13.2% | 145.5% | 0.587 |
| Cerebrovascular disorders | 3(9.7%) | 218.3% | 0.794 |
| Chronic Kidney Disease | 412.9% | 259.9% | 0.599 |
| Pulmonary embolism | 329.6% | 166.3% | 0.480 |
| ALT (U/l) | 203±68826 [5; 3036]36 | 70±17639 [7; 1697]37 | 0.255 |
| AST (U/l) | 325±106041 [10; 4661]78 | 94±24045 [9; 2317]41 | 0.797 |
| CRP (mg/l) | 14.5±9.513.6 [0.8; 38.9]9.8 | 10.4±8.38 [0.1; 59.2]11.4 | |
| Ferritin (μg/l) | 2617±29941442 [507; 11712]1268 | 1432±2024812 [21; 17118]1234 | |
| WBC (10/l) | 13,8±12.0710.44 [2.72; 59.54]8.19 | 9.87±8.037.95 [1.46; 64.85]6.06 | |
| Urea (mg/dl) | 89±8067 [21; 417]45 | 64±5544 [7; 360]46 | |
| Albumin (g/dl) | 2.7±0.62.8 [1.1; 3.4]0.6 | 3.1±0.53.1 [1.9; 4.3]0.9 | |
| CT scan severity index (points) | 17.9±5.119 [6; 23]7 | 14.5±5.915 [0; 25]9 | |
| Hospital stay (days) | 12 SD 7.6Median 11.7IQR 9.8 | 11.6 SD 7.7Median 10.3IQR9.7 | 0.492 |
| Deaths | 23 (74.2) | 77 (30.4) | |